SCHEMBL1068342

SCHEMBL1068342

CCOC(=O)/C=C(/CBr)Oc1c(F)ccc(OC)c1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.36
MEP1B Q16820 1/20 0.36
MAOB P27338 1/20 0.35
MAPT P10636 3/20 0.33
ALDH1A1 P00352 2/20 0.33
LMNA P02545 2/20 0.33
HPGDS O60760 1/20 0.33
BCHE P06276 2/20 0.33
ACHE P22303 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 1/20 0.33
PRKCZ Q05513 1/20 0.32
PLIN1 O60240 1/20 0.32
POLB P06746 1/20 0.32
PLIN5 Q00G26 1/20 0.32
ABHD5 Q8WTS1 1/20 0.32
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1068339 1.00 FDPS (0.36) FDPSMEP1BMAOBMAPTALDH1A1
SCHEMBL1068344 1.00 FDPS (0.36) FDPSMEP1BMAOBMAPTALDH1A1
SCHEMBL1065728 0.91 ALDH1A1 (0.33) FDPSMEP1BMAPTALDH1A1LMNA
SCHEMBL1065722 0.91 ALDH1A1 (0.33) FDPSMEP1BMAPTALDH1A1LMNA
SCHEMBL1065725 0.91 ALDH1A1 (0.33) FDPSMEP1BMAPTALDH1A1LMNA
SCHEMBL1066326 0.87 P2RX3 (0.35) MEP1BMAPTALDH1A1MEN1KMT2A
SCHEMBL1066325 0.87 P2RX3 (0.35) MEP1BMAPTALDH1A1MEN1KMT2A
SCHEMBL1066323 0.87 P2RX3 (0.35) MEP1BMAPTALDH1A1MEN1KMT2A
SCHEMBL1067979 0.84 CYP4F2 (0.35) MEP1BMAPTALDH1A1LMNAMEN1
SCHEMBL1068450 0.84 CYP4F2 (0.35) MEP1BMAPTALDH1A1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2274297-B1 PYRROLIDINONE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2012-05-09 EP disclosed
EP-2274297-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-19 EP disclosed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 US disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127546-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 FDPS 819/4885MEP1B 1818/4885MAOB 2769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.